Vesicular phospholipid injectable composition for prolonged release of glatiramer or its salt and preparation method thereof
Vesicular phospholipid gel formulations address the challenges of frequent injections by providing prolonged and consistent release of glatiramer, ensuring high drug loading and stability, thus improving patient compliance and comfort.
Patent Information
- Application Number
- PCT/IN2026/050779
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current formulations of glatiramer acetate require frequent injections, leading to injection site reactions and reduced patient compliance, and existing prolonged-release strategies face challenges in achieving high drug load with long-term stability using complex and costly methods.
Development of vesicular phospholipid gel (VPG) formulations that form a depot at the injection site, providing prolonged and consistent release of glatiramer or its salts for up to one month, with high drug loading capacity and stability, using a simple and cost-effective process.
The VPG formulations achieve ideal characteristics for prolonged release, maintaining structural integrity and stability, reducing injection frequency, and enhancing patient comfort and adherence.
Smart Images

Figure IMGF000013_0001_TABLE 
Figure IMGF000013_0002_TABLE 
Figure IMGF000014_0001_TABLE
Abstract
Description
[0001] Vesicular Phospholipid Injectable composition for Prolonged Release of Glatiramer or its salt and preparation methods thereof
[0002] CROSS REFERENCE
[0003] This application claims the priority of Indian provisional applications IN202541043729 filed on 06thMay 2025.
[0004] FIELD OF THE INVENTION
[0005] The present invention relates to a pharmaceutical composition for prolonged release of a pharmaceutically active compound using a vesicular phospholipid formulation which forms depot at injection site. In particular, the invention discloses pharmaceutical composition for prolonged release of a glatiramer or its salt thereof, the composition comprising a vesicular phospholipid formulation which forms in-situ depot at injection site and provides consistent release for prolonged period. Furthermore, the present invention relates to a method of preparation of such compositions.
[0006] BACKGROUND
[0007] Glatiramer and its salts (such as glatiramer acetate) is a synthetic polypeptide used primarily for the treatment of relapsing-remitting multiple sclerosis (MS). Glatiramer acetate is composed of acetate salts of four amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine. The clear mechanism by which glatiramer works effectively in MS patients is not understood. However, glatiramer acetate is thought to act by modifying immune processes that are responsible for the pathogenesis of MS. Studies conducted in animals and in vitro systems indicate that when glatiramer acetate is administered, it triggers the induction and activation of suppressor T-cells specific to glatiramer acetate in the peripheral immune system.
[0008] Currently glatiramer acetate is available in the form of subcutaneous injection and marketed under brand names like Copaxone® and Glatopa®. These are available in two strengths 20 mg / mL which needs to be administered daily & 40 mg / mL which needs to be administered three times a week, with each dose separated by at least 48 hours. This standard administration frequency gives rise to challenges such as injection site reactions, patient discomfort, and reduced compliance. Therefore, there is a need for a prolonged-release formulation of glatiramer acetate.Several strategies have been explored to develop prolonged-release formulation of glatiramer acetate aiming to reduce injection frequency and improve patient compliance. These strategies include in situ gels using polymers such as polaxamer, modified chitosan, hyaluronic acid, microsphere based extended-release systems, and liposomal based systems. These advanced systems involve use of organic solvents and complex methods of preparation such as size reduction and homogenization methods. Despite these advancements, a key challenge persists in creating a formulation that can incorporate a high drug load while maintaining long-term stability with simple cost-effective process that uses safer solvent & avoids the need for intricate preparation techniques.
[0009] Vesicular phospholipid gel (VPG) systems offer a compelling solution to address these challenges. VPGs are highly concentrated dispersions of phospholipids that form semi-solid, gellike structures with vesicular morphology. These systems provide several advantages, such as high drug encapsulation efficiency, prolonged and controlled release profiles, and excellent stability. Unlike liposomal systems, which are often prone to leakage and degradation, VPGs maintain structural integrity over extended periods, making them ideal for long-term storage and sustained drug release.
[0010] Hence the objective of the present invention is to overcome the limitations of existing formulations by developing Vesicular phospholipid gel formulations of glatiramer or salt thereof having higher drug loading capacity and stability while providing prolonged & consistent release of the glatiramer or salt thereof by forming depot at injection site thereby reducing the frequency of injections and enhancing patient comfort and adherence. Another objective of the present invention is to provide a preparation process for these formulations.
[0011] SUMMARY OF THE INVENTION
[0012] The present invention discloses vesicular phospholipid gel (VPG) formulations of glatiramer and its salts. In particular, the invention discloses a stable vesicular phospholipid formulation of glatiramer acetate which accommodates high load of the glatiramer acetate. Further, such formulation forms a depot at injection site upon administration and releases drug consistently for up to one month. The disclosed formulations of the invention exhibit ideal characteristics for a prolonged-acting formulation as demonstrated by in vitro characterizations, including gel formation, zeta-potential, vesicles size and morphology, syringeability, injectability, and drug release.
[0013] In one aspect, the present invention discloses vesicular phospholipid gel formulations of glatiramer or salt thereof comprising glatiramer or salt thereof and one or more phospholipids.Suitable salts of glatiramer include, without limitation, acetate, chloride, bromide, phosphate, sulfate, and citrate salts. The one or more phospholipids are selected without limitations, from the group comprising of phosphatidylinosites phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, cephalines, lysolecithines, phosphatidylglycerols, soya phosphatidylcholine (soya PC), or egg phosphatidylcholine (egg PC) or mixtures of these phospholipids.
[0014] In another aspect, the disclosed formulations of present invention further comprises one or more pharmaceutically acceptable excipients. The one or more acceptable excipients without limitations, selected from the group comprising preservative(s), buffer(s), antioxidant(s), stabilizer(s), pH modifier(s), and surfactant(s), or a combination thereof.
[0015] In yet another aspect, the present invention discloses vesicular phospholipid formulations of glatiramer or salt thereof having prolonged and consistent release for upto one month.
[0016] The present invention further discloses a process for preparation of a stable pharmaceutical formulation of glatiramer or salt thereof, wherein the process comprises dissolving glatiramer or salt thereof in suitable buffer, followed by addition of phospholipid, and mixing thoroughly. Further, the present invention optionally comprises pharmaceutically acceptable excipients.
[0017] DETAILED DESCRIPTION OF THE INVENTION
[0018] The present invention discloses a stable vesicular phospholipid gel formulations of glatiramer or salt thereof which comprises one or more phospholipids and optionally one or more pharmaceutically acceptable excipients for prolonged release.
[0019] DEFINITIONS
[0020] The term “about" refers to a range of values that are similar to the stated reference value and includes a range of values that fall within 20% or less, preferably 10% of the stated reference value.
[0021] As used in this specification, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to “a method” or “a process” includes one or more methods, one or more processes and / or steps of the type described herein and / or which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.
[0022] The term “Glatiramer” or “Active Ingredient” herein refers to a pharmaceutically active molecule as well as its pharmaceutically acceptable and therapeutically active salts, esters, amides, prodrugs, metabolites, enantiomers, polymorphs, analogues, etc. that induce a desiredpharmacological or physiological effect. Terms like “active”, “active agent”, and “active substance” may be used synonymously for “active ingredient” and / or “Glatiramer”.
[0023] The term “formulation” or “dosage form” or “pharmaceutical formulation” or “formulation” as used herein synonymously refers to injectable or parenteral dosage forms or any other suitable dosage form meant for parenteral administration. The pharmaceutical formulation includes immediate release, fast release, modified release, delayed release, pulsed release formulations, and the like.
[0024] The term “stable” according to present invention refers to a pharmaceutical formulation in which the amount of impurity(ies) remains below FDA / ICH acceptable intake limit after exposure of the pharmaceutical formulation to 40 °C ± 5 °C / 75% ± 5% RH for a period of at least six months or 25 °C ± 5 °C / 60% ± 5% RH for a period of at least 12 months or 2-8 °C for a period of at least 24 months.
[0025] The term "comprising" used herein is a transitional phrase to introduce elements or steps of an invention. It is an open-ended term, meaning that it does not exclude additional elements or steps that are not explicitly mentioned. In simpler terms, "comprising" indicates that the list of elements or steps is not exhaustive and can include other unspecified components.
[0026] The term “depot” used herein refers to a temporary matrix inside a biological tissue or system, which includes a pharmaceutically active compound that is released from the matrix over a period of time.
[0027] The term “excipient” or “pharmaceutically acceptable excipients” means a pharmacologically inactive component such as a surfactant, pH modifier, antioxidant, preservative, release modifying polymers and like, of a pharmaceutical product. The excipients may also include excipients for providing fast release, immediate release, extended release, delayed release, pulsed release, and the like. The excipients that are useful in preparing a dosage form are generally safe, non-toxic, and acceptable for veterinary as well as human pharmaceutical use. Reference to an excipient includes both one excipient and more than one excipient.
[0028] The term “phospholipids,” as used herein, refers to a class of amphiphilic molecules that form the structural basis of vesicular systems such as vesicular phospholipid gels (VPGs). Suitable phospholipids include, without limitation, natural phospholipids, synthetic phospholipids, and semi-synthetic phospholipids.Natural phospholipids include, without limitation, soya phosphatidylcholine (soya PC), egg phosphatidylcholine (egg PC), phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, and phosphatidylserine. Other examples of natural phospholipids include lysophosphatidylcholine (lyso-PC) and hydrogenated natural phospholipids such as hydrogenated soya phosphatidylcholine (HSPC).
[0029] Synthetic phospholipids suitable for use include, without limitation, dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE), distearoylphosphatidylethanolamine (DSPE), and their derivatives such as polyethylene glycol (PEG)-conjugated phospholipids, e.g., DSPE-PEG2000 and DSPE-PEG5000.
[0030] Semi-synthetic phospholipids include, without limitation, derivatives like palmitoyl-oleoyl-phosphatidylcholine (POPC) and stearoyl-oleoyl-phosphatidylcholine (SOPC).
[0031] The term “one or more acceptable excipients,” as used herein, includes, without limitation, preservatives such as benzyl alcohol, phenol, methylparaben, propylparaben, sodium benzoate, potassium sorbate, chlorobutanol, thimerosal, or combinations thereof; buffers such as sodium citrate, sodium acetate, potassium phosphate, sodium phosphate, phosphate -buffered saline (PBS), tris(hydroxymethyl)aminomethane (TRIS), or combinations thereof; antioxidants such as ascorbic acid, tocopherols (Vitamin E), butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), sodium metabisulfite, glutathione, or combinations thereof; stabilizers such as polyethylene glycol (PEG), poloxamers, dextran, cyclodextrins, sucrose fatty acid esters, trehalose, albumin, or combinations thereof; pH modifiers such as hydrochloric acid, sodium hydroxide, citric acid, lactic acid, acetic acid, phosphate salts, or combinations thereof; and surfactants such as polysorbates (e.g., Tween 20, Tween 80), lecithin, sorbitan esters (Span 20, Span 60, Span 80), sodium lauryl sulfate, cetylpyridinium chloride, or combinations thereof.
[0032] Additionally, some excipients may be incorporated with phospholipids to enhance the structural integrity, rigidity, and stability of vesicles. Stabilizing agents include, without limitation, cholesterol tocopherols such as Vitamin E, stearylamine, phytosterols such as sitosterol and campesterol, Other suitable stabilizing agents include sphingomyelin, PEGylated phospholipids like DSPE-PEG2000 or DSPE-PEG5000, ceramides, fatty alcohols such as cetyl alcohol or stearyl alcohol. These stabilizing agents may be employed individually or in combination to achieveoptimal stability and performance of vesicular phospholipid gel systems for drug delivery applications.
[0033] In an embodiment, the present invention discloses a stable vesicular phospholipid gel formulation for prolonged release of glatiramer or salt thereof comprising glatiramer or salt thereof and one or more phospholipids. Suitable salts of glatiramer include, without limitation, acetate, chloride, bromide, phosphate, sulfate, and citrate salts.
[0034] In a further embodiment of the above, the present invention discloses a stable vesicular phospholipid gel formulation for prolonged release of glatiramer or salt thereof which comprises glatiramer or salt thereof, one or more phospholipids and optionally one or more pharmaceutically acceptable excipients.
[0035] In the above mentioned embodiment, the one or more pharmaceutically acceptable excipients are selected without limitation, from water, buffer(s), antioxidant(s), preservative(s), stabilizer(s), and pH modifier(s).
[0036] In the above mentioned embodiment of the invention, the buffers are selected from sodium acetate, sodium citrate, phosphate-buffered saline (PBS), potassium phosphate, sodium phosphate, tris(hydroxymethyl)aminomethane (TRIS), or combinations thereof.
[0037] In the above mentioned embodiment of aforesaid embodiment, wherein the stabilizers are selected from without limitation, cholesterol, sphingomyelin, vitamin E, lipids, fatty alcohols or combinations thereof.
[0038] In any of above mentioned embodiments of present invention, wherein the preservatives are selected from without limitation, as benzyl alcohol, phenol, methylparaben, propylparaben, sodium benzoate, potassium sorbate, chlorobutanol, thimerosal, or combinations thereof.
[0039] In any of the above mentioned embodiment of the invention, wherein the one or more phospholipids is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, phosphatidylserines, cephalins, lysolecithins, phosphatidylglycerols and mixtures of several such phospholipids.
[0040] In an embodiment the present invention discloses a stable vesicular phospholipid gel formulation of glatiramer or salt thereof comprising glatiramer or salt thereof, soya phosphatidylcholine and a buffer.In an embodiment the present invention discloses a stable vesicular phospholipid gel formulation of glatiramer or salt thereof comprising glatiramer or salt thereof, soya phosphatidylcholine and a buffer selected from sodium acetate, sodium citrate, phosphate buffered saline.
[0041] In an embodiment the present invention discloses a stable vesicular phospholipid gel formulation of glatiramer or salt thereof comprising glatiramer or salt thereof, egg phosphatidylcholine and a buffer.
[0042] In an embodiment the present invention discloses a stable vesicular phospholipid gel formulation of glatiramer or salt thereof comprising glatiramer or salt thereof, egg phosphatidylcholine and a buffer selected from sodium acetate, sodium citrate, phosphate buffered saline.
[0043] In certain embodiments of the present invention, the vesicular phospholipid formulation comprises from about 1 mg to about 100 mg of glatiramer or its salt thereof. In certain other embodiments, the vesicular phospholipid formulation comprises from about 10 mg to about 80 mg of glatiramer or its salt thereof. In certain embodiments, the vesicular phospholipid formulation comprises glatiramer or salt thereof from about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg and about 100 mg.
[0044] In yet another embodiment, the present invention discloses a stable vesicular phospholipid gel formulation for prolonged release of glatiramer or salt thereof which comprises glatiramer or salt thereof, egg phosphatidylcholine, soya phosphatidylcholine and optionally one or more pharmaceutically acceptable excipients.
[0045] In above mentioned embodiment, the ratio of Egg PC to soya PC is from about 99:1 to about 1:99 by weight. In particular embodiments, the ratio ranges from about 95:5 to about 50:50 by weight, more particularly from about 90: 10 to about 60:40 by weight.
[0046] In a more specific embodiment, the ratio of egg phosphatidylcholine to soya PC is selected from the group consisting of 95:5, 90: 10, 80:20, 70:30, 60:40, and 50:50 by weight.
[0047] In the above mentioned embodiment of aforesaid embodiments, one or more pharmaceutically acceptable excipients are selected without limitation, from buffer(s), antioxidant(s), preservative(s), stabilizer(s), and pH modifier(s).In the above mentioned embodiment of the invention, the buffers are selected from sodium acetate, sodium citrate, potassium phosphate, phosphate -buffered saline (PBS), sodium phosphate, tris(hydroxymethyl)aminomethane (TRIS), or combinations thereof.
[0048] In the above mentioned embodiment of aforesaid embodiment of the present invention, wherein the stabilizers are selected from without limitation, cholesterol, sphingomyelin, vitamin E, lipids, fatty alcohols or combinations thereof.
[0049] In yet another embodiment, the present invention discloses a stable vesicular phospholipid formulation for prolonged release of glatiramer or salt thereof which comprises glatiramer or salt thereof, egg phosphatidylcholine, soya phosphatidylcholine, a buffer selected from sodium acetate, phosphate buffer saline and a stabilizer selected from cholesterol, sphingomyelin, vitamin E, lipids, fatty alcohols or combinations thereof.
[0050] In another embodiment the present invention discloses a method of preparation of stable vesicular phospholipid formulation for prolonged release of glatiramer or salt thereof comprising:
[0051] i) dissolving glatiramer or salt thereof in a buffer to obtain a clear solution
[0052] ii) addition of phospholipids to the solution obtained in the step i) and mixing to obtain stable vesicular phospholipid formulation for prolonged release of glatiramer.
[0053] In above mentioned embodiment of present invention, wherein the method of preparation comprises dissolving glatiramer or salt thereof in a buffer and adding phospholipid followed by thorough mixing.
[0054] In yet another embodiment the present invention discloses a method of preparation of stable vesicular phospholipid formulation for prolonged release of glatiramer or salt thereof comprising:
[0055] i) dissolving glatiramer or salt thereof in water to obtain a clear solution
[0056] ii) addition of phospholipids to the solution obtained in the step i) and mixing to obtain stable vesicular phospholipid formulation for prolonged release of glatiramer.
[0057] In a further embodiment of the invention discloses a stable vesicular phospholipid formulation for prolonged release of glatiramer or salt thereof prepared by said method comprising a) dissolving glatiramer acetate in sodium acetate buffer b) addition of phospholipids selected from group comprising soya phosphatidylcholine (soya PC) or egg phosphatidylcholine (egg PC) or combinations thereof followed by thorough mixing.In above mentioned embodiment of present invention, the method optionally comprises addition of one or more pharmaceutically acceptable excipients and the excipients are selected from the group consisting of antioxidants, preservative, pH modifiers can be added.
[0058] In yet another embodiment, the present invention discloses a method of preparation of stable vesicular phospholipid formulation for prolonged release of glatiramer or salt thereof wherein the method comprises
[0059] i) dissolving glatiramer or salt thereof in a buffer to obtain a clear solution
[0060] ii) adding one or more phospholipids to the solution obtained in the step i) and mixing
[0061] iii) adding a stabilizer suspension and mixing to obtain stable vesicular phospholipid formulation for prolonged release of glatiramer.
[0062] In above mentioned embodiment, the stabilizer suspension is prepared by dissolving the stabilizer together with one or more surfactant in an organic solvent to form a stabilizer solution, followed by removal of the solvent to obtain a residue and hydration of the residue with an aqueous medium or buffer to form the stabilizer suspension. This solvent removal may be carried out using solvent evaporation techniques including, but not limited to, rotary evaporation, reduced-pressure evaporation, thin-fdm evaporation, or equivalent solvent-removal methods. Further, mixing steps may be carried out using stirring, homogenization, sonication, or combinations thereof, to obtain vesicles exhibiting physical and chemical stability and controlled release characteristics.
[0063] In a further embodiment, the method of preparation as described above, wherein the buffer comprises sodium acetate, phosphate buffered saline or combination thereof.
[0064] In a further embodiment, the method of preparation as described above, wherein the one or more phospholipids comprise egg phosphatidylcholine, soya phosphatidylcholine or combination thereof.
[0065] In a further embodiment, the method of preparation as described above, wherein the stabilizer comprises cholesterol.
[0066] In yet another embodiment, the method of preparation as described above, wherein the one or more phospholipids comprise egg phosphatidylcholine and soya phosphatidylcholine, and wherein the stabilizer comprises cholesterol.In a still further embodiment, the method of preparation as described above, wherein the stabilizer suspension comprises cholesterol and one or more surfactants, dissolved in an organic solvent, followed by solvent removal and hydration to obtain the stabilizer suspension.
[0067] In yet another embodiment, the present invention discloses a stable vesicular phospholipid formulation for prolonged release of glatiramer or salt thereof which comprises glatiramer or salt thereof, egg phosphatidylcholine, soya phosphatidylcholine, a buffer selected from sodium acetate, phosphate buffer saline and a stabilizer selected from cholesterol, sphingomyelin, vitamin E, lipids, fatty alcohols or combinations thereof prepared by method comprising:
[0068] i) dissolving glatiramer or salt thereof in a sodium acetate buffer to obtain a clear solution
[0069] ii) adding soya phosphatidyl choline and egg phosphatidylcholine to the solution obtained in the step i) and mixing
[0070] iii) adding a cholesterol suspension and mixing to obtain stable vesicular phospholipid formulation for prolonged release of glatiramer.
[0071] In yet another embodiment, the present invention discloses a stable vesicular phospholipid formulation for prolonged release of glatiramer or salt thereof which comprises glatiramer or salt thereof, egg phosphatidylcholine, soya phosphatidylcholine, a buffer selected from sodium acetate, phosphate buffer saline and a stabilizer selected from cholesterol, sphingomyelin, vitamin E, lipids, fatty alcohols or combinations thereof prepared by method comprising:
[0072] i) dissolving glatiramer or salt thereof in a phosphate buffer saline to obtain a clear solution
[0073] ii) adding soya phosphatidyl choline and egg phosphatidylcholine to the solution obtained in the step i) and mixing
[0074] iii) adding a cholesterol suspension and mixing to obtain stable vesicular phospholipid formulation for prolonged release of glatiramer.
[0075] In the above mentioned embodiment, the ratio of Egg PC to soya PC is from about 99: 1 to about 1:99 by weight. In particular embodiments, the ratio ranges from about 95:5 to about 50:50 by weight, more particularly from about 90: 10 to about 60:40 by weight.
[0076] In a more specific embodiment, the ratio of egg phosphatidylcholine to soya PC is selected from the group consisting of 95:5, 90:10, 80:20, 70:30, 60:40, and 50:50 by weight.In yet another embodiment of the present invention discloses a stable vesicular phospholipid formulation for prolonged release of glatiramer or salt thereof, comprising:
[0077] a) glatiramer or salt thereof;
[0078] b) one or more phospholipids;
[0079] c) a buffer; and
[0080] d) optionally, one or more stabilizers.
[0081] In above mentioned embodiment of the present invention, the phospholipids are selected from soya phosphatidylcholine (soya PC) or egg phosphatidylcholine (egg PC) or a combination thereof wherein phospholipids are present in an amount from about 10% to about 50%w / w.
[0082] In any of the above mentioned embodiment of the present invention, the buffer is selected sodium acetate, sodium citrate, potassium phosphate, phosphate buffered saline (PBS), sodium phosphate, tris(hydroxymethyl)aminomethane (TRIS), or combinations thereof.
[0083] In any of the above mentioned embodiment of the present invention, the stabilizers are selected from cholesterol, sphingomyelin, vitamin E, lipids, fatty alcohols or combinations thereof.
[0084] In any of the above mentioned embodiment of the present invention, further comprising one or more pharmaceutically acceptable excipients.
[0085] In any of the above mentioned embodiment of the present invention, the pharmaceutically acceptable excipients are selected from antioxidants, preservatives, stabilizers, and pH modifiers.
[0086] In yet another embodiment of the present invention discloses a stable vesicular phospholipid formulation for prolonged release of glatiramer or its salt thereof, comprising: a) glatiramer or its salt thereof;
[0087] b) about 10% to about 40% w / w soy phosphatidylcholine;
[0088] c) phosphate-buffered saline; and
[0089] d) cholesterol.
[0090] In above mentioned embodiment of the present invention, wherein the formulation comprises about 30% w / w soya phosphatidylcholine.
[0091] In yet another embodiment of the present invention discloses a process for preparing a stable vesicular phospholipid formulation for prolonged release of glatiramer or a its salt thereof,comprising:
[0092] i) dissolving glatiramer or its salt thereof in a buffer to obtain a solution;
[0093] ii) adding one or more phospholipids and mixing; and
[0094] iii) optionally adding a stabilizer and mixing.
[0095] In any of the above embodiments, the phospholipid concentration ranges from about 10 % w / w to about 50 % w / w of total composition. In particular, the phospholipid concentration is about 10 % w / w, about 15 % w / w, about 20 % w / w, about 25 % w / w, about 30 % w / w, about 35 % w / w, about 40 % w / w, about 45 % w / w or about 50 % w / w.
[0096] In any of the above embodiments, the phospholipids are selected from soya phosphatidylcholine (soya PC) or egg phosphatidylcholine (egg PC) or combinations thereof. In particular, soya PC or egg PC concentration is within the range of about 10 % w / w to about 50 % w / w. In particular, the egg PCor Soya PC concentration is about 10 % w / w, about 15 % w / w, about 20 % w / w, about 25 % w / w, about 30 % w / w, about 35 % w / w, about 40 % w / w, about 45 % w / w or about 50 % w / w.
[0097] In any of the above embodiments the glatiramer acetate concentration ranges from about 1-100 mg / mL.
[0098] In any of the above mentioned embodiments of the present invention the weight ratio between phospholipid and glatiramer acetate is between 1000:1 and 4:1.
[0099] In any of the above mentioned embodiment of present invention, the disclosed formulation comprises glatiramer or salt thereof and one or more phospholipid forms depot upon injection and provides prolonged release for at least 10 days or at least 15 days or at least 1 month or at least 2 months or at least 3 months or at least 6 months.
[0100] The disclosed formulation of the invention is used for the treatment of multiple sclerosis.
[0101] Certain specific aspects and embodiments of the invention are more fully described by reference to the following examples. However, these examples should not be construed as limiting the scope of the invention in any manner.
[0102] Examples
[0103] Example 1: Optimization of Phospholipid composition for Blank VPG
[0104] Blank VPGs were prepared using Phosphatidylcholine as the lipid component and an aqueous buffer as the hydration medium. Phospholipids comprising Egg PC or Soy PC or Egg PC with SoyPC combination with various ratio were weighed and aq phase contains of 0.1M sodium acetate buffer (pH 4.0) was gradually added to the phospholipid under continuous stirring. The phospholipids self-assembled into densely packed vesicles forming semisolid VPG were stored at 2-8°C.
[0105] Gelation behavior of the prepared blank VPG was evaluated by an injection-induced gelation test. Approximately 4 mL of phosphate-buffered saline (PBS, pH 7.4) was transferred into a glass vial. About 0.5 mL of the prepared VPG formulation was loaded into a syringe and injected slowly into the PBS medium with the needle immersed below the liquid surface. Upon contact with PBS, the formulation rapidly formed a cohesive gel mass, confirming the ability of the vesicular phospholipid formulation to undergo in situ gelation under physiological conditions.
[0106] Characterization :
[0107] Table 1: Blank VPG Formulations with varying amount of Egg PC and Soya PC characterized for particle size, polydispersity index (PDI), and zeta potential using dynamic light scattering Formulation Particle Size PDI Zeta Potential Syringeability / [%w / w] (nm) (mV) Injectability Egg PC 30% 1770 0.74 -10.07 Good Soy PC 30% 2314 0.96 +4.13 Good Egg PC 35% 2004 1.00 -11.63 Decent Soy PC 35% 2037 0.61 +6.62 Decent Egg PC 40% 1081 0.86 -1.15 Tricky
[0108]
[0109] Soy PC 40% 3610 0.63 +11.65 Tricky Table 2: Blank VPG Formulations with different ratios of Egg PC and Soya PC combinations characterized for particle size, polydispersity index (PDI), and zeta potential using dynamic light scattering
[0110] Formulation [Egg PC: Soy L Particle Size PDI Zeta Potential Syringeability /
[0111] Ratio] (nm) (mV) Injectability Egg PC 95% _ Soy L 5% 966.1 0.71 -12.3 Good Egg PC 90% _ Soy L 10% 890.8 0.92 -15.19 Easy & Good Egg PC 80% _ Soy L 20% 634.6 0.84 -21.2 Easy & Good Egg PC 70% _ Soy L 30% 403.1 1.00 -24.22 Tricky Egg PC 60% _ Soy L 40% 425.1 0.86 -29.86 Easy & Good
[0112]
[0113] Egg PC 50% _ Soy L 50% 438.9 0.75 -36.02 Decent The trial screened blank VPGs with different amounts of egg PC or Soya PC or VPGs prepared by combination of both with different ratios to develop a stable VPG. Although gelation was good with the combined phospholipid systems, 30% w / w soy PC showed the most promising characteristics.Example 2: Additional blank VPG were prepared using buffer systems, co-solvents and stabilizing agents
[0114] Additional placebo VPG formulations were prepared using buffer systems, co-solvents, and stabilizing agents. These tested components included:
[0115] • PBS buffer
[0116] • acetate buffer
[0117] . DMSO
[0118] • N-methyl-2-pyrrolidone (NMP)
[0119] • ethanol
[0120] • PEG-400
[0121] • Tween-80
[0122] For ImL VPG formulation, Composition was SPC-70%, Buffer-30%. For further composition details of additives and stabilizers refer Table 3 and Table 4.
[0123] Table 3. Preparation of VPG with Stabilizer / Phospholipid compatible components.
[0124] Trials Proportions of Observation / Results
[0125] excipients
[0126] VPG with Suffer system
[0127] 1 SPC+PBS VPs formed, and gelation was observed
[0128] 2 SPC + Acetate buffer VPs formed, and gelation was observed
[0129] VPG with Buffer (PBS) + Solvent
[0130] 3 SPC + DMSO (1% ) + VPs formed, and gelation was poor
[0131] PBS
[0132] 4 SPC + NMP (1%) + VPs formed, poor gelation (floating
[0133] PBS was observed as soon as injection and
[0134] started to dispersion after 3 mins)
[0135] 5 SPC + Ethanol (1% )+ VPs formed, and gelation was observed
[0136] PBS a floating occurred immediately after
[0137] injection a dispersion began
[0138] 6 SPC + PEG-400 (1% ) + VPs formeda poor gelation a floating
[0139] PBS occurred immediately after injection a
[0140] dispersion began
[0141] VPG with Buffer (Acetate Buffer) + Solvent
[0142] 7 SPC + DMSO (1% ) + VPs formeda poor gelation a floating
[0143] Acetate buffer occurred immediately after injection a
[0144]
[0145] dispersion began8 SPC + NMP (1% ) + VPs formeda poor gelation a floating
[0146] Acetate buffer occurred immediately after injection a
[0147] dispersion began
[0148] 9 SPC + Ethanol (1% ) + VPs formeda poor gelation a floating
[0149] Acetate buffer occurred immediately after injection a
[0150] dispersion began
[0151] 10 SPC + PEG-400 (1% ) + VPs formed, and gelation was observed
[0152] Acetate buffer
[0153] VPG with stabilizer
[0154] 11 SPC+ Tween 80 + PBS Foamy VPs formed; consistency was
[0155] poor, and no gelation was observed
[0156] 12 SPC+ Tween 80 (0.5% Foamy VPs formed; consistency was
[0157]
[0158] & 1%) + Acetate buffer poor, and no gelation was observed
[0159] For placebo optimization, PBS and acetate buffer systems supported gelation, while PEG-400 improved performance in acetate buffer. In contrast, NMP, ethanol, DMSO, and Tween 80 adversely affected gel strength and stability. PBS (pH 7.4) was selected as the final buffer due to better overall compatibility
[0160] Example 3: Blank Vesicular Phospholipid Gel Formulations Comprising Phospholipids and Cholesterol as stabilizer
[0161] A series of blank vesicular phospholipid gel (VPG) formulations were prepared to evaluate the role of cholesterol as a stabilizer within the phospholipid matrix. Soya phosphatidylcholine (SPC) were tested at varying phospholipid-to-cholesterol ratios ranging from 95:5 to 70:30.
[0162] Table 4: Blank VPG formulations with varying amounts of Cholesterol
[0163] Code Composition Observation Gelling ability
[0164] F 1 SPC (95%) Moderate viscous Able to form gel, low intact,
[0165] + gel, optimal flow Dispersion has occurred after Cholesterol 10 mins of injection
[0166] (5%)
[0167] F 2 SPC (90 %) Thick gel, Free Good gelling ability, More
[0168] + flow intact than F 1
[0169] Cholesterol
[0170] (10%)
[0171] F 3 SPC (80 %) Phase separation Good gelling ability, More
[0172] + has occurred, intact , Slightly hard to inject
[0173] shows gel
[0174]
[0175] Cholesterol consistency upon
[0176] (20 %) shaking
[0177] F 4 SPC (70 %) Phase separation Good gelling ability, More
[0178] + has occurred, intact , Slightly hard to inject Cholesterol shows gel
[0179] (30 %) consistency upon
[0180] shaking
[0181]
[0182] Example 4: GLAC loaded VPG (30% w / w) [GLAC-VPG30]
[0183] Glatiramer acetate (50 mg) was mixed with sodium acetate buffer (0.7 mL) or PBS buffer. To prepare 30% wt. phospholipid composition, 0.3 g of Soya PC or Egg PC phospholipid was transferred to the above solution, the mixture was vortexed with a magnetic bead for 10 minutes, then placed on a magnetic stirrer using a holder and stirred for 20 minutes at 1500 rpm for Ih at room temperature (24 °C).
[0184] Similarly, GLAC loaded VPG of other concentration such as 25%, 35% & 40% were prepared using Soya PC or Egg PC phospholipid.
[0185] Characterization :
[0186] For characterization studies blank VPG were prepared in following manner and studied by microscopy, size & surface charge, density, gelation & drug release.
[0187] To prepare blank VPG 25% wt., 30% wt. 35% wt, 40 % wt phospholipid composition, required amount PC or Egg PC phospholipid was dissolved in sodium acetate buffer and the mixture was vortexed for 10 minutes then placed on a magnetic stirrer using a holder and stirred for 20 minutes at 1500 rpm for Ih at room temperature (24 °C).
[0188] 1. Microscopy: Microscopic analysis demonstrated the formation of lipid vesicles composed of both Soya PC Phospholipids and Egg PC Phospholipids. Vesicle sizes were primarily distributed in the range of 1-5 pm, with occasional larger aggregates approximately 8-15 pm. The formulation exhibited a homogeneous distribution of vesicles. Incorporation of the active pharmaceutical ingredient into the formulation was found to have no significant impact on the morphology or size distribution of the vesicles, confirming the stability and integrity of the vesicular structure post drug loading.
[0189] 2. Determination of Size and Surface ChargeThe sample preparation involved diluting 10 pL of the formulations prepared according to example 1 into 990 pL of distilled water to achieve an appropriate dispersion. Zeta Potential analysis confirmed the presence of nearly neutral particles, which is advantageous for aggregation during gel formation. The particle size was measured in the range of approximately 1-9 pm.
[0190] Table 5: Particle Size, PDI, and Zeta Potential of VPG Formulations
[0191] No. Formulation Particle Size PDI Zeta Potential (pm) (mV) Soya PC-Based Formulations
[0192] (SPC)
[0193] 1 Blank VPG SPC 30% w / w 2.3 0.96 +4.134 2 GLAC VPG SPC 30% w / w 8.5 0.73 -0.78
[0194] 3 Blank VPG SPC 35% w / w 2.0 0.61 +6.62
[0195] 4 GLAC VPG SPC 35% w / w 2.5 0.59 -1.7
[0196] Egg PC-Based Formulations (EPC)
[0197] 5 GLAC VPG EPC 25% w / w 2.0 0.52 -2.3
[0198] 6 Blank VPG EPC 30% w / w 1.8 0.74 -10.07
[0199] 7 GLAC VPG EPC 30% w / w 4.5 1 -7.79
[0200] 8 Blank VPG EPC 35% w / w 2.0 1 -11.63
[0201] 9 GLAC VPG EPC 35% w / w 2.9 0.50 -2.6
[0202]
[0203] 10 Blank VPG EPC 40% w / w 1.1 0.86 -1.15
[0204] The data obtained from the analysis of Vesicular Phospholipid Gel (VPG) formulations highlights the consistency in particle size, polydispersity index (PDI), and zeta potential across formulations based on Soya Phospholipids (SPC) and Egg Phospholipids (EPC). The near-neutral zeta potential observed in Soya PC formulations supports their aggregation during gel formation.
[0205] 3. Gelation study for analyzing the depot-forming capacity of the formulation at physiological pH.
[0206] For this process, 4 ml of PBS was taken in a glass vial, to which 0.5 ml of the formulation was injected by using 2 ml syringe. While injecting the formulation, the needle was dipped in the buffer solution and the plunger was gradually pressed. Gelation was observed. The gelation process demonstrates favorable characteristics for the GLAC-Soy PC 30% w / w formulation, this specific composition exhibits superior properties, including enhanced gel uniformity, structural stability, and homogeneity within the phosphate-buffered saline (PBS).
[0207] 4. Densities of Vesicular Phospholipid Gel (VPG) Formulations
[0208] The densities of VPG formulations were determined using a Density Meter (DMA 35 Version 3 Basic) to assess variations across different compositions. Both Soya PC (SPC)-based and Egg PC(EPC)-based formulations were analyzed, including blank and GLAC-loaded variants, as summarized below Table 6:
[0209] No. Formulation Density
[0210] (g / cm3)
[0211] Soya PC-Based Formulations (SPC)
[0212] 1 30% w / w SPC VPG Blank 0.988
[0213] 2 30% w / w SPC_GLAC VPG (1 mg / mL) 0.992
[0214] 3 35% w / w SPC VPG Blank 0.954
[0215] 4 35% w / w SPC_GLAC VPG (1 mg / mL) 0.984
[0216] Egg PC-Based Formulations (EPC)
[0217] 5 30% w / w EPC VPG Blank 0.963
[0218] 6 30% w / w EPC_GLAC VPG (1 mg / mL) 0.981
[0219] 7 35% w / w EPC VPG Blank 0.968
[0220]
[0221] 8 35% w / w EPC_GLAC VPG (1 mg / mL) 0.97
[0222] The results indicate notable differences in densities among the formulations depending on the type and concentration of phospholipids used. Soya PC -based formulations exhibited slightly higher density values upon GLAC incorporation, with the 30% w / w SPC_GLAC VPG (1 mg / mL) formulation achieving the highest density of 0.992 g / cm3. Similarly, Egg PC -based formulations demonstrated comparable trends, with the 30% w / w EPC_GLAC VPG (1 mg / mL) formulation achieving a density of 0.981 g / cm3.
[0223] 5. Drug Release Data
[0224] To analyze in vitro drug release, 1 mL of the formulation containing 50 mg of GLAC was taken in the dialysis bag having cutoff value of 14,000 Da. It was dipped in sample vial containing 35 ml of PBS (pH 7.4) containing disodium ethylenediaminetetraacetate dihydrate (EDTA, 0.05% w / v, serve as antibacterial additive), tightly closed and placed in water-bath shaker with reciprocating shaking at 37 °C at 100 rpm. In another example, formulation was directly injected at the bottom of 15 mL Falcon tube filled with 10 mL of PBS buffer and kept at 37 °C without shaking. Sample was taken for analysis at decided time points and analyzed by UV spectrophotometry method at Xmax = 275nm.
[0225] Specifics:
[0226] Amount of formulation kept for drug release= ImL
[0227] Wavelength = 275nm
[0228] Baseline Correction was done using solution containing PBS (pH 7.4) with blank VPG.
[0229] Bath Volume= 35ml, Sampling Volume= 20pL diluted to 3 mL with PBS buffer.The drug release profile of the GLAC-loaded SPC VPG 30% and GLAC-loaded EPC VPG 30% formulation demonstrates a sustained release over an extended period.
[0230] Example 5: Preparation of Sterile Glatiramer-Loaded VPG (SPC + Cholesterol) for Animal Trial
[0231] A sterile vesicular phospholipid gel formulation containing glatiramer acetate was prepared under aseptic conditions.
[0232] Table 7: Composition for 35 mL batch:
[0233] Component Quantity
[0234] Glatiramer acetate* 2.8 g
[0235] SPC 10.5 g
[0236] PBS (pH 7.4) 12.25 mL
[0237]
[0238] Cholesterol suspension** 12.25 mL
[0239] * Drug loading is 80 mg / ml.
[0240] ** The cholesterol suspension consisted of cholesterol and Span 60 in a 3:2 ratio.
[0241] Preparation Method:
[0242] A. Preparation of Cholesterol Suspension
[0243] 1. Cholesterol and Span 60 were placed in a round -bottom flask.
[0244] 2. Dichloromethane was added to dissolve the lipids.
[0245] 3. The solvent was removed using a rotary evaporator at 55 °C and 60 rpm.
[0246] 4. After solvent removal, PBS was added and the mixture was sonicated for 30 minutes. 5. The volume was adjusted to 14 mL with PBS, followed by vortexing and additional sonication to obtain a homogeneous cholesterol suspension.
[0247] B. Preparation of GLAC-VPG
[0248] 1. Glatiramer acetate was dissolved in PBS to obtain an API solution.
[0249] 2. The API solution was mixed with cholesterol suspension to obtain an APLcholesterol mixture.
[0250] 3. SPC was weighed into multiple centrifuge tubes.
[0251] 4. APLcholesterol mixture was added to each tube containing SPC.
[0252] 5. The mixture was vortexed for 15 minutes to obtain vesicular phospholipid gel.
[0253] 6. All formulations were pooled and vortexed again to ensure uniform distribution of vesicles. The resulting VPG formulation was packaged into sterile containers and stored at 2-8 °C.
[0254] Table 8. Characterization of GLAC-Loaded VPG [Composition of Example 5]Parameter Result
[0255] Average particle size 2423 nm
[0256] PDI 0.41
[0257] Zeta potential +0.31 mV
[0258] Density 1.021 g / cm3
[0259]
[0260] Viscosity 4587 mPa-s
[0261] No new impurities were detected following incorporation of the API into the VPG system.
[0262] Table 9. Homogeneity of GLAC-Loaded VPG [Composition of Example 5 ]
[0263] Detected API,
[0264] Sample Deviation, mg % Deviation*
[0265] mg
[0266] 1 9.99 0.16 1.63 %
[0267] 2 10.36 0.53 5.39 %
[0268] 3 9.13 0.7 7.12 %
[0269]
[0270] Average 9.83 0.46 4.71 %
[0271] * Average drug content (130 pL sample): 9.83 ± 0.46 mg
[0272] Table 10. In Vitro Drug Release [Composition of Example 5 ]
[0273] Time (days) BatchA (%) Batch B (%)
[0274] 2 0 3.06
[0275] 15 25.62 29.35
[0276] 18 65.88 78.97
[0277] 23 84.65 78.02
[0278] 28 91.63 94.75
[0279]
[0280] 30 100 100
[0281] *Drug release was evaluated in PBS (pH 7.4) containing sodium azide. The formulation exhibited sustained drug release over approximately 30 days.
[0282] The VPG showed a mean particle size of 2,423 nm with a PDI of 0.41, indicating a moderately uniform system. The zeta potential was nearly neutral at +0.31 mV, while the density and viscosity were 1.021 g / cm3and 4,587 mPa.s, respectively. No new impurities were detected after API loading, and the homogeneity value of 9.83 + 0.46 mg was close to the expected content of 10.4 mg, suggesting good content uniformity. Drug release was sustained in Batch A up to day 55, whereas Batch B showed complete release by day 60.
[0283] Stability Evaluation of GLAC-VPG (Example 5)
[0284] Stability testing of the sterile GLAC-VPG formulation was conducted at:
[0285] • 2-8 °C
[0286] . 25 °CThe formulation was evaluated after 1 month for physical appearance, particle size, zeta potential, homogeneity, syringeability, gel formation and drug release. After one month, samples stored at 2-8 °C retained their original appearance and physicochemical properties, while samples stored at room temperature exhibited phase separation and partial precipitation (Table 7, 8).
[0287] These results indicate that refrigerated storage conditions are preferable for maintaining formulation stability.
[0288] Table 11. Stability Evaluation of GLAC - VPG (Example 5)
[0289] S.No Parameters Condition: 2-8°C Condition: RT
[0290] 1 Physical appearance Retained original Phase separation
[0291] consistency / white occurred / white
[0292] color color
[0293] 2 Aggregation / Precipitation No aggregation No aggregation;
[0294] precipitation
[0295] observed, with
[0296] lipids settling at
[0297] the bottom of the
[0298] tube after phase
[0299] separation
[0300] 3 Syringeability Good VPG was
[0301] redispersed by
[0302] gentle shaking
[0303] before injection.
[0304] 4 Avg. Particle size (nm) 2400.66 1624.83
[0305] 5 PDI 0.54 0.60
[0306] 6 ZP (mV) +1.72 mV +0.68 mV
[0307] 7 Homogeneity (mg) Batch A: 11.33 + Batch A: 6.49 +
[0308] Expected API Content: 0.04 mg 0.11 mg
[0309] 130 pL x 80 mg / mL = Batch B: 9.99 + Batch B: 9.04 +
[0310] 10.4 mg 0.26 mg 0.16 mg
[0311]
[0312] Table 12. In Vitro Drug Release (%) of One-Month Stability Samples (HPLC Method)
[0313] Time Batch A (2- Batch B (2- Batch A (RT) Batch B
[0314] (Days)* 8 °C) 8 °C) (RT)
[0315] 0 6.56 7.88 0 0
[0316] 1 18.00 20.69 4.63 4.88
[0317] 3 31.56 38.13 9.56 9.63
[0318] 5 46.13 56.56 19.25 20.94
[0319]
[0320] 10 68.00 78.63 41.13 47.13*Day 0 corresponds to approximately 4 hours after initiation of the experiment.
[0321] Batches A, B share an identical chemical composition. These batches represent independent technical replicates of a single formulation, prepared to demonstrate process consistency and statistical reproducibility.
[0322] After one month of storage, the sample maintained at 2-8°C showed better physical stability and homogeneity compared with the room temperature sample. The refrigerated sample retained its original white consistency, exhibited no aggregation or phase separation, and showed acceptable syringeability, whereas the room temperature sample showed phase separation, lipid settling, and reduced homogeneity. These findings indicate that refrigeration is more suitable for maintaining the stability of the formulation,
[0323] Example 6: Animal Studies
[0324] Composition of example 5 was evaluated in vivo in an experimental autoimmune encephalomyelitis (EAE) model (C57BL / 6 mouse model). EAE is a powerful tool for studying the mechanisms of neuroinflammation, immune cell behavior, and testing potential therapies for MS. It mimics many features of human MS. Clinical scoring was initiated from day-7 following immunization and treatment on day-1 (subcutaneous route, 10 mg / kg dose). Disease was monitored over 28 days. Mean clinical scores showed a decrease in score i.e., improvement in disease post one single injection of glatiramer loaded VPG formulation. It can be attributed to sustained release of glatiramer from depot formulation for longer duration. Moreover, once a month formulation showed decrease in area under the effect curve and reduction in disease. To summarize, formulation has shown potential of disease improvement post a single injection.
[0325] Hence the formulation of present invention showed ideal characteristics of a long-acting formulation based on several in vitro characterization, including Gel formation, Zeta-potential, Vesicles size and morphology, syringeability, injectability, drug release data and animal studies data.
Claims
Claims1. A stable vesicular phospholipid formulation for prolonged release of glatiramer or salt thereof, comprising:a) glatiramer or salt thereof;b) one or more phospholipids;c) a buffer; andd) optionally, one or more stabilizers.
2. The formulation according to claim 1, wherein the phospholipids are selected from soya phosphatidylcholine (soya PC) or egg phosphatidylcholine (egg PC) or a combination thereof wherein phospholipids are present in an amount from about 10% to about 50%w / w.
3. The formulation according to claim 1, wherein the buffer is selected sodium acetate, sodium citrate, potassium phosphate, phosphate buffered saline (PBS), sodium phosphate, tris(hydroxymethyl)aminomethane (TRIS), or combinations thereof.
4. The formulation according to claim 1, the stabilizers are selected from cholesterol, sphingomyelin, vitamin E, lipids, fatty alcohols or combinations thereof.
5. The formulation according to claim 1, further comprising one or more pharmaceutically acceptable excipients.
6. The formulation according to claim 5, the pharmaceutically acceptable excipients are selected from antioxidants, preservatives, stabilizers, and pH modifiers.
7. A stable vesicular phospholipid formulation for prolonged release of glatiramer or its salt thereof, comprising:a) glatiramer or its salt thereof;b) about 10% to about 40% w / w soy phosphatidylcholine;c) phosphate-buffered saline; andd) cholesterol.
8. The formulation according to claim 7, wherein the formulation comprises about 30% w / w soya pho sphatidylcholine9. A process for preparing a stable vesicular phospholipid formulation for prolonged release of glatiramer or its salt thereof, comprising:i) dissolving glatiramer or its salt thereof in a buffer to obtain a solution;ii) adding one or more phospholipids and mixing; andiii) optionally adding a stabilizer and mixing.
